Jpmorgan Chase & CO Repligen Corp Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Repligen Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 193,499 shares of RGEN stock, worth $27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
193,499
Previous 169,190
14.37%
Holding current value
$27 Million
Previous $31.1 Million
21.61%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RGEN
# of Institutions
494Shares Held
53.8MCall Options Held
420KPut Options Held
85.3K-
Black Rock Inc. New York, NY7.57MShares$1.06 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.07MShares$707 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.61MShares$643 Million0.07% of portfolio
-
State Street Corp Boston, MA1.74MShares$242 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.42MShares$198 Million0.55% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.74B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....